Taysha Gene Therapies (TSHA) Tops Q1 EPS by 1c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $1.91 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Morgan Stanley Starts Amplifon SpA (AMP:IM) (AMFPF) at Overweight
• GitLab Inc (GTLB) Tops Q2 EPS by 7c, Beats on Revenue
• Morgan Stanley Upgrades Coloplast A/S (COLOB:DC) (CLPBY) to Equalweight